Probiotec
Market Cap
AU$133.1m
Last Updated
2020/09/30 10:32 UTC
Data Sources
Company Financials +
Executive Summary
Probiotec Limited engages in the development, manufacture and sale of pharmaceuticals, consumer health, and nutraceutical products in Australia and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with excellent balance sheet and pays a dividend.
Share Price & News
How has Probiotec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PBP has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.6%
PBP
2.3%
AU Pharmaceuticals
2.8%
AU Market
1 Year Return
-5.6%
PBP
-24.4%
AU Pharmaceuticals
-10.6%
AU Market
Return vs Industry: PBP exceeded the Australian Pharmaceuticals industry which returned -24.4% over the past year.
Return vs Market: PBP exceeded the Australian Market which returned -10.6% over the past year.
Shareholder returns
| PBP | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.6% | 2.3% | 2.8% |
| 30 Day | -3.8% | 5.5% | -1.8% |
| 90 Day | -8.7% | 5.3% | 2.5% |
| 1 Year | -3.7%-5.6% | -24.3%-24.4% | -7.4%-10.6% |
| 3 Year | 238.3%212.3% | -25.4%-26.7% | 18.0%2.8% |
| 5 Year | 529.7%439.4% | -27.7%-31.8% | 42.1%12.9% |
Price Volatility Vs. Market
How volatile is Probiotec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Probiotec Limited (ASX:PBP) Shares Could Be 44% Below Their Intrinsic Value Estimate1 month ago | Simply Wall St
Is Probiotec Limited (ASX:PBP) Trading At A 44% Discount?2 months ago | Simply Wall St
Do Its Financials Have Any Role To Play In Driving Probiotec Limited's (ASX:PBP) Stock Up Recently?Valuation
Is Probiotec undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PBP (A$1.78) is trading below our estimate of fair value (A$3.57)
Significantly Below Fair Value: PBP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PBP is good value based on its PE Ratio (19.5x) compared to the XO Pharmaceuticals industry average (48.5x).
PE vs Market: PBP is good value based on its PE Ratio (19.5x) compared to the Australian market (20.4x).
Price to Earnings Growth Ratio
PEG Ratio: PBP is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: PBP is good value based on its PB Ratio (2.2x) compared to the AU Pharmaceuticals industry average (2.9x).
Next Steps
Future Growth
How is Probiotec forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
17.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBP's forecast earnings growth (17.4% per year) is above the savings rate (2.3%).
Earnings vs Market: PBP's earnings (17.4% per year) are forecast to grow faster than the Australian market (17.2% per year).
High Growth Earnings: PBP's earnings are forecast to grow, but not significantly.
Revenue vs Market: PBP's revenue (12.8% per year) is forecast to grow faster than the Australian market (4.4% per year).
High Growth Revenue: PBP's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PBP's Return on Equity is forecast to be low in 3 years time (14.7%).
Next Steps
Past Performance
How has Probiotec performed over the past 5 years?
29.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PBP has high quality earnings.
Growing Profit Margin: PBP's current net profit margins (6%) are higher than last year (5.1%).
Past Earnings Growth Analysis
Earnings Trend: PBP's earnings have grown significantly by 29.4% per year over the past 5 years.
Accelerating Growth: PBP's earnings growth over the past year (71.9%) exceeds its 5-year average (29.4% per year).
Earnings vs Industry: PBP earnings growth over the past year (71.9%) underperformed the Pharmaceuticals industry 117.8%.
Return on Equity
High ROE: PBP's Return on Equity (10.6%) is considered low.
Next Steps
Financial Health
How is Probiotec's financial position?
Financial Position Analysis
Short Term Liabilities: PBP's short term assets (A$46.2M) exceed its short term liabilities (A$25.7M).
Long Term Liabilities: PBP's short term assets (A$46.2M) do not cover its long term liabilities (A$47.9M).
Debt to Equity History and Analysis
Debt Level: PBP's debt to equity ratio (18.7%) is considered satisfactory.
Reducing Debt: PBP's debt to equity ratio has reduced from 29.4% to 18.7% over the past 5 years.
Debt Coverage: PBP's debt is well covered by operating cash flow (90%).
Interest Coverage: PBP's interest payments on its debt are well covered by EBIT (4.7x coverage).
Balance Sheet
Next Steps
Dividend
What is Probiotec current dividend yield, its reliability and sustainability?
2.53%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: PBP's dividend (2.53%) is higher than the bottom 25% of dividend payers in the Australian market (2.32%).
High Dividend: PBP's dividend (2.53%) is low compared to the top 25% of dividend payers in the Australian market (5.58%).
Stability and Growth of Payments
Stable Dividend: PBP's dividend payments have been volatile in the past 10 years.
Growing Dividend: PBP's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (49.2%), PBP's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PBP's dividends in 3 years are forecast to be well covered by earnings (45.4% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average board tenure
CEO
Wes Stringer
5.17yrs
Tenure
AU$535,288
Compensation
Mr. Wesley Stringer, also known as Wes, B.Comm (Accounting, Finance), LLB (Hons), CPA, has been the Chief Executive Officer of Probiotec Limited since July 1, 2015 and serves as its managing Director. Mr. ...
CEO Compensation Analysis
Compensation vs Market: Wes's total compensation ($USD381.12K) is above average for companies of similar size in the Australian market ($USD278.57K).
Compensation vs Earnings: Wes's compensation has increased by more than 20% in the past year.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 5.17yrs | AU$535.29k | 6.59% A$ 8.8m | |
| Independent Chairman | 0.17yr | AU$53.33k | 0.24% A$ 319.6k | |
| Independent Non-Executive Director | 3.5yrs | AU$54.67k | 0.15% A$ 202.5k | |
| Non-Executive Director | 0.25yr | AU$4.83k | 0.064% A$ 84.5k |
1.9yrs
Average Tenure
Experienced Board: PBP's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.6%.
Top Shareholders
Company Information
Probiotec Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Probiotec Limited
- Ticker: PBP
- Exchange: ASX
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$133.106m
- Shares outstanding: 74.78m
- Website: https://www.probiotec.com.au
Location
- Probiotec Limited
- 83 Cherry Lane
- Laverton North
- Victoria
- 3026
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PBP | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Nov 2006 |
| PBP | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Nov 2006 |
Biography
Probiotec Limited engages in the development, manufacture and sale of pharmaceuticals, consumer health, and nutraceutical products in Australia and internationally. The company provides contract manufactur ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/30 10:32 |
| End of Day Share Price | 2020/09/30 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.